

AC Quiza PE 200

Axichem Pty Ltd

Chemwatch: 5192-12

Version No: 9.1

Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Chemwatch Hazard Alert Code: 3

Issue Date: 27/10/2023

Print Date: 16/02/2024

L.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	AC Quiza PE 200
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains quizalofop-P-ethyl)
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Selective post-emergence herbicide.
--------------------------	-------------------------------------

Details of the manufacturer or supplier of the safety data sheet

Registered company name	Axichem Pty Ltd
Address	9 Palings Court Nerang QLD 4211 Australia
Telephone	07 5596 1736
Fax	Not Available
Website	www.axichem.com.au
Email	msds@axichem.com.au

Emergency telephone number

Association / Organisation	CHEMWATCH EMERGENCY RESPONSE (24/7)
Emergency telephone numbers	+61 1800 951 288
Other emergency telephone numbers	+61 3 9573 3188

Once connected and if the message is not in your preferred language then please dial 01

SECTION 2 Hazards identification

Classification of the substance or mixture

COMBUSTIBLE LIQUID, regulated for storage purposes only

Poisons Schedule	S6
Classification ^[1]	Flammable Liquids Category 4, Acute Toxicity (Oral) Category 4, Aspiration Hazard Category 1, Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Specific Target Organ Toxicity - Single Exposure (Narcotic Effects) Category 3, Reproductive Toxicity Category 1A, Hazardous to the Aquatic Environment Long-Term Hazard Category 2
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

Label elements

Hazard pictogram(s)	
---------------------	---

Signal word	Danger
-------------	--------

Hazard statement(s)

H227	Combustible liquid.
H302	Harmful if swallowed.
H304	May be fatal if swallowed and enters airways.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H360D	May damage the unborn child.
H411	Toxic to aquatic life with long lasting effects.

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P271	Use only outdoors or in a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P261	Avoid breathing mist/vapours/spray.
P264	Wash all exposed external body areas thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P273	Avoid release to the environment.

Precautionary statement(s) Response

P301+P310	IF SWALLOWED: Immediately call a POISON CENTER/doctor/physician/first aider.
P331	Do NOT induce vomiting. If more than 15 mins from Doctor, INDUCE VOMITING (if conscious).
P308+P313	IF exposed or concerned: Get medical advice/ attention.
P370+P378	In case of fire: Use alcohol resistant foam or normal protein foam to extinguish.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337+P313	If eye irritation persists: Get medical advice/attention.
P391	Collect spillage.
P301+P312	IF SWALLOWED: Call a POISON CENTER/doctor/physician/first aider if you feel unwell.
P302+P352	IF ON SKIN: Wash with plenty of water.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P330	Rinse mouth.
P332+P313	If skin irritation occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.

Precautionary statement(s) Storage

P405	Store locked up.
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
------	--

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
100646-51-3	20	<u>quizalofop-P-ethyl</u>
Various	59	<u>liquid hydrocarbons</u>
872-50-4	15	<u>N-methyl-2-pyrrolidone</u>
Not Available	<10	Ingredients determined not to be hazardous

Legend: 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	<p>If this product comes in contact with the eyes:</p> <ul style="list-style-type: none"> Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	<p>If skin contact occurs:</p> <ul style="list-style-type: none"> Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	<ul style="list-style-type: none"> If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor.
Ingestion	<ul style="list-style-type: none"> For advice, contact a Poisons Information Centre or a doctor. If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice.

Indication of any immediate medical attention and special treatment needed

For acute or short term repeated exposures to petroleum distillates or related hydrocarbons:

- Primary threat to life, from pure petroleum distillate ingestion and/or inhalation, is respiratory failure.
- Patients should be quickly evaluated for signs of respiratory distress (e.g. cyanosis, tachypnoea, intercostal retraction, obtundation) and given oxygen. Patients with inadequate tidal volumes or poor arterial blood gases (pO₂ 50 mm Hg) should be intubated.
- Arrhythmias complicate some hydrocarbon ingestion and/or inhalation and electrocardiographic evidence of myocardial injury has been reported; intravenous lines and cardiac monitors should be established in obviously symptomatic patients. The lungs excrete inhaled solvents, so that hyperventilation improves clearance.
- A chest x-ray should be taken immediately after stabilisation of breathing and circulation to document aspiration and detect the presence of pneumothorax.
- Epinephrine (adrenalin) is not recommended for treatment of bronchospasm because of potential myocardial sensitisation to catecholamines. Inhaled cardioselective bronchodilators (e.g. Alupent, Salbutamol) are the preferred agents, with aminophylline a second choice.
- Lavage is indicated in patients who require decontamination; ensure use of cuffed endotracheal tube in adult patients. [Ellenhorn and Barceloux: Medical Toxicology]

SECTION 5 Firefighting measures

Extinguishing media

- Water spray or fog.
- Foam.
- Dry chemical powder.
- BCF (where regulations permit).

- ▶ Carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility	▶ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
-----------------------------	--

Advice for firefighters

Fire Fighting	<ul style="list-style-type: none"> ▶ Alert Fire Brigade and tell them location and nature of hazard. ▶ Wear breathing apparatus plus protective gloves. ▶ Prevent, by any means available, spillage from entering drains or water courses. ▶ Use water delivered as a fine spray to control fire and cool adjacent area. ▶ DO NOT approach containers suspected to be hot. ▶ Cool fire exposed containers with water spray from a protected location. ▶ If safe to do so, remove containers from path of fire. ▶ Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	<ul style="list-style-type: none"> ▶ Combustible. ▶ Slight fire hazard when exposed to heat or flame. ▶ Heating may cause expansion or decomposition leading to violent rupture of containers. ▶ On combustion, may emit toxic fumes of carbon monoxide (CO). ▶ May emit acrid smoke. ▶ Mists containing combustible materials may be explosive. <p>Combustion products include: carbon dioxide (CO₂) chlorides nitrogen oxides (NO_x) other pyrolysis products typical of burning organic material. May emit poisonous fumes.</p>
HAZCHEM	•3Z

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	<p>Environmental hazard - contain spillage.</p> <ul style="list-style-type: none"> ▶ Remove all ignition sources. ▶ Clean up all spills immediately. ▶ Avoid breathing vapours and contact with skin and eyes. ▶ Control personal contact with the substance, by using protective equipment. ▶ Contain and absorb spill with sand, earth, inert material or vermiculite. ▶ Wipe up. ▶ Place in a suitable, labelled container for waste disposal.
Major Spills	<p>Environmental hazard - contain spillage. Moderate hazard.</p> <ul style="list-style-type: none"> ▶ Clear area of personnel and move upwind. ▶ Alert Fire Brigade and tell them location and nature of hazard. ▶ Wear breathing apparatus plus protective gloves. ▶ Prevent, by any means available, spillage from entering drains or water course. ▶ No smoking, naked lights or ignition sources. ▶ Increase ventilation. ▶ Stop leak if safe to do so. ▶ Contain spill with sand, earth or vermiculite. ▶ Collect recoverable product into labelled containers for recycling. ▶ Absorb remaining product with sand, earth or vermiculite. ▶ Collect solid residues and seal in labelled drums for disposal. ▶ Wash area and prevent runoff into drains. ▶ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	<ul style="list-style-type: none">Avoid all personal contact, including inhalation.Wear protective clothing when risk of exposure occurs.Use in a well-ventilated area.Prevent concentration in hollows and sumps.DO NOT enter confined spaces until atmosphere has been checked.Avoid smoking, naked lights or ignition sources.Avoid contact with incompatible materials.When handling, DO NOT eat, drink or smoke.Keep containers securely sealed when not in use.Avoid physical damage to containers.Always wash hands with soap and water after handling.Work clothes should be laundered separately.Use good occupational work practice.Observe manufacturer's storage and handling recommendations contained within this SDS.Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.DO NOT allow clothing wet with material to stay in contact with skin
Other information	<ul style="list-style-type: none">Store in original containers.Keep containers securely sealed.No smoking, naked lights or ignition sources.Store in a cool, dry, well-ventilated area.Store away from incompatible materials and foodstuff containers.Protect containers against physical damage and check regularly for leaks.Observe manufacturer's storage and handling recommendations contained within this SDS.Protect from light.

Conditions for safe storage, including any incompatibilities

Suitable container	<ul style="list-style-type: none">Metal can or drumPackaging as recommended by manufacturer.Check all containers are clearly labelled and free from leaks.
Storage incompatibility	Avoid storage with oxidisers

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	N-methyl-2-pyrrolidone	1-Methyl-2-pyrrolidone	25 ppm / 103 mg/m3	309 mg/m3 / 75 ppm	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
N-methyl-2-pyrrolidone	30 ppm	32 ppm	190 ppm


Ingredient	Original IDLH	Revised IDLH
quizalofop-P-ethyl	Not Available	Not Available
liquid hydrocarbons	Not Available	Not Available
N-methyl-2-pyrrolidone	Not Available	Not Available

MATERIAL DATA

None assigned. Refer to individual constituents.

Exposure controls

Appropriate engineering controls	<p>Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.</p> <p>The basic types of engineering controls are:</p> <p>Process controls which involve changing the way a job activity or process is done to reduce the risk.</p> <p>Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.</p>
----------------------------------	---

	<p>Employers may need to use multiple types of controls to prevent employee overexposure.</p> <p>General exhaust is adequate under normal operating conditions. If risk of overexposure exists, wear SAA approved respirator. Correct fit is essential to obtain adequate protection. Provide adequate ventilation in warehouse or closed storage areas. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.</p> <table border="1"> <thead> <tr> <th>Type of Contaminant:</th><th>Air Speed:</th></tr> </thead> <tbody> <tr> <td>solvent, vapours, degreasing etc., evaporating from tank (in still air)</td><td>0.25-0.5 m/s (50-100 f/min)</td></tr> <tr> <td>aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)</td><td>0.5-1 m/s (100-200 f/min.)</td></tr> <tr> <td>direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)</td><td>1-2.5 m/s (200-500 f/min)</td></tr> <tr> <td>grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).</td><td>2.5-10 m/s (500-2000 f/min.)</td></tr> </tbody> </table> <p>Within each range the appropriate value depends on:</p> <table border="1"> <thead> <tr> <th>Lower end of the range</th><th>Upper end of the range</th></tr> </thead> <tbody> <tr> <td>1: Room air currents minimal or favourable to capture</td><td>1: Disturbing room air currents</td></tr> <tr> <td>2: Contaminants of low toxicity or of nuisance value only</td><td>2: Contaminants of high toxicity</td></tr> <tr> <td>3: Intermittent, low production.</td><td>3: High production, heavy use</td></tr> <tr> <td>4: Large hood or large air mass in motion</td><td>4: Small hood - local control only</td></tr> </tbody> </table> <p>Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min.) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.</p>	Type of Contaminant:	Air Speed:	solvent, vapours, degreasing etc., evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min)	aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)	direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min)	grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)	Lower end of the range	Upper end of the range	1: Room air currents minimal or favourable to capture	1: Disturbing room air currents	2: Contaminants of low toxicity or of nuisance value only	2: Contaminants of high toxicity	3: Intermittent, low production.	3: High production, heavy use	4: Large hood or large air mass in motion	4: Small hood - local control only
Type of Contaminant:	Air Speed:																				
solvent, vapours, degreasing etc., evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min)																				
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)																				
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min)																				
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)																				
Lower end of the range	Upper end of the range																				
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents																				
2: Contaminants of low toxicity or of nuisance value only	2: Contaminants of high toxicity																				
3: Intermittent, low production.	3: High production, heavy use																				
4: Large hood or large air mass in motion	4: Small hood - local control only																				
Individual protection measures, such as personal protective equipment																					
Eye and face protection	<ul style="list-style-type: none"> ▶ Safety glasses with side shields; or as required, ▶ Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent] ▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59]. 																				
Skin protection	See Hand protection below																				
Hands/feet protection	<ul style="list-style-type: none"> ▶ Wear chemical protective gloves, e.g. PVC. ▶ Wear safety footwear or safety gumboots, e.g. Rubber 																				
Body protection	See Other protection below																				
Other protection	<ul style="list-style-type: none"> ▶ Overalls. ▶ P.V.C apron. ▶ Barrier cream. ▶ Skin cleansing cream. ▶ Eye wash unit. 																				

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the

computer-generated selection:

AC Quiza PE 200

Respiratory protection

Type AK-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Material	CPI
BUTYL	A
PE/EVAL/PE	A
NATURAL RUBBER	B
PVA	B

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 5 x ES	AK-AUS / Class 1 P2	-	AK-PAPR-AUS / Class 1 P2
up to 25 x ES	Air-line*	AK-2 P2	AK-PAPR-2 P2
up to 50 x ES	-	AK-3 P2	-
50+ x ES	-	Air-line**	-

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO₂), G = Agricultural chemicals, K = Ammonia(NH₃), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Clear amber liquid with characteristic odour; mixes with water.		
Physical state	Liquid	Relative density (Water = 1)	~1.0
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	>61	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Combustible.	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	0.2 approx.	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	<ul style="list-style-type: none"> ▶ Unstable in the presence of incompatible materials. ▶ Product is considered stable. ▶ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	<p>Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system.</p> <p>Acute effects from inhalation of high concentrations of vapour are pulmonary irritation, including coughing, with nausea; central nervous system depression - characterised by headache and dizziness, increased reaction time, fatigue and loss of co-ordination</p>
Ingestion	<p>Ingestion may result in nausea, pain, vomiting. Vomit entering the lungs by aspiration may cause potentially lethal chemical pneumonitis.</p>
Skin Contact	<p>Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period.</p> <p>Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis.</p> <p>Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.</p>
Eye	<p>Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals.</p> <p>Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.</p>
Chronic	<p>Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems.</p> <p>There is sufficient evidence to provide a strong presumption that human exposure to the material may result in developmental toxicity, generally on the basis of:</p> <ul style="list-style-type: none"> - clear results in appropriate animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. <p>Chronic solvent inhalation exposures may result in nervous system impairment and liver and blood changes. [PATTYS]</p>

AC Quiza PE 200	TOXICITY	IRRITATION
	Not Available	Not Available
quizalofop-P-ethyl	TOXICITY	IRRITATION
	dermal (rat) LD50: 1852 mg/kg ^[2]	Skin (rabbit): None *
	Inhalation(Rat) LC50: 2.6 mg/l4h ^[2]	
	Oral (Rat) LD50: 1182 mg/kg ^[2]	
liquid hydrocarbons	TOXICITY	IRRITATION
	Not Available	Not Available
N-methyl-2-pyrrolidone	TOXICITY	IRRITATION
	Dermal (rabbit) LD50: 8000 mg/kg ^[2]	Eye (rabbit): 100 mg - moderate *[Manufacturer]
	Inhalation(Rat) LC50: 3.1-8.8 mg/l4h ^[2]	
	Oral (Rat) LD50: 3914 mg/kg ^[2]	

Legend: 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

QUIZALOFOP-P-ETHYL	<p>- for quizalofop-P-ethyl Inhalation (rat) LC50: 4.4 mg/l/4h female ** NOEL (90 d) for rats 128 mg/kg * Toxicity Class: EPA III for quizalofop-ethyl NOEL (104 weeks) for rats 25 pm; (78 weeks) for mice 10 ppm * Toxicity Class WHO III; EPA III * Non-mutagenic in Ames and REC tests * Non-sensitising to guinea pig skin * * The Pesticide Manual. NOTE: The Pesticide Manual appears to have confused acute dermal results with subcutaneous data reported in RTECS. ** DuPont MSDS Targa Herbicide (9.64 % active ingredient)</p> <p>ACCcase plays a vital role in mammalian systems for fatty acid biosynthesis, the enzyme existing in two isozymic forms. This enzyme is highly regulated in the brain and non-neural tissue. None of these forms are inhibited by cyclohexanediones or aryloxyphenoxypyrrolidones. Although these herbicides affect common target sites in plants and mammals, they have no effect on ACCase in mammals.</p>
--------------------	---

for quizalofop-p-ethyl (as a representative of the aryloxyphenoxypropionate group of herbicides):

Acute toxicity: Quizalofop-p-ethyl is nonirritating to the skin and only slightly irritating to the eyes in rabbits. It is nonsensitising to the skin of guinea pigs.

Chronic toxicity: In a 1-year feeding study on dogs, doses of up to 10 mg/kg/day quizalofop-p-ethyl (the highest dose tested in that study) caused no observed effects. In a 90-day feeding study in rats, doses of 6.4 mg/kg/day and higher produced liver lesions and increased liver weight.

In a 2-year feeding study conducted with rats with the racemic mixture of quizalofop-p-ethyl isomers, the no-observable-effect level (NOEL) was 25 ppm (1.25 mg/kg/day) based on liver effects which occurred at 100 ppm. There was a slight but non-significant increase in female liver tumours at 400 ppm. The material was non-oncogenic in this species. In an 18-month feeding study with mice, the NOEL was 10 ppm (1.5 mg/kg/day) based on effects on liver and testes at 80 ppm. An increase in liver carcinomas was observed in male mice and an increased incidence of ovarian tumours (leuteomas and granulosa cell tumours) were observed in female mice. These effects were statistically significant at 320 ppm (48 mg/kg/day). In a 1-year feeding study with dogs, the NOEL was 400 mg (30 mg/kg/day) with no compound-related effects apparent.

Reproductive toxicity: Data from reproductive studies indicated only decreased body weight gains, and did not report findings of impaired reproductive function in test animals. A 6-month study in dogs found atrophy of the semeniferous tubules at doses of 2.5 mg/kg/day, but was unclear whether this was extensive enough to result in impaired reproductive function. These data are insufficient to draw conclusions regarding the likely reproductive effects of quizalofop-p-ethyl in animals, but suggest that effects on human reproduction are unlikely under normal circumstances.

In a reproductive study conducted with rats, parents and off-spring showed body weight decreases at 400 ppm. Histological changes in liver were observed at 100 ppm. The NOEL was 25 ppm (approximately 1.25 mg/kg/day).

Developmental toxicity: In teratogenic studies, there was no evidence of teratogenicity or embryotoxicity at levels up to 60 mg/kg/day. Body weight gain and other toxic effects were seen in pregnant rabbits at 60 mg/kg/day. Overall NOEL was 30 mg/kg/day. The product was not teratogenic to rats at dose levels of up to 300 mg/kg/day. Reduced body weight gains were evident in dams at 300 mg/kg. Offspring of this treatment group exhibited reduced survival and a transient increase in skeletal variations. The NOEL for this group was 30 mg/kg/day.

Genotoxicity: The results of many assays for mutagenicity and genotoxicity of quizalofop-p-ethyl show no mutagenic or genotoxic activity. Negative results were obtained in the Ames and Chinese hamster ovary (CHO) test for gene mutation, the CHO and mouse micronucleus tests for chromosomal aberration, DNA repair assays in *B. subtilis* and rat liver cells, and sister chromatid exchange assay in Chinese hamster cells.

Carcinogenic effects: In an 18-month carcinogenicity study on mice, increased liver weights, changes in blood chemistry, and some changes in liver tissue structure were detected, but no carcinogenic or tumor-causing activity was reported. This study suggests that this compound is not carcinogenic.

Organ toxicity: Available data show that the target organ in test animals has consistently been the liver in rats and dogs [8]. It is possible that testes may be a target organ in some species; e.g., dogs.

Fate in humans and animals: Quizalofop-p appears to be rapidly broken down in mammals. More than 90% of a single oral dose is eliminated in urine within 3 days.

Inhibitors of acetyl CoA carboxylase, the target enzyme of certain herbicides, have the capacity, in mammals, to alter blood lipid levels. In the male rat, a reduction ($p < 0.05$) in blood cholesterol and total lipids in a chronic study may be a reflection of inhibition of this enzyme. However, in the female mouse, there was an increase in blood cholesterol at the highest dose tested, in a subchronic study. Male mice in this study showed an increase in total lipids at the two highest doses. It is therefore possible that many of the effects reported in acute, subchronic and chronic studies are manifestations of a compromise of normal liver function. The inhibition of fatty acid biosynthesis, in the liver, may account for the majority of the effects observed. However, increases in liver weight, seen in acute and sub-chronic studies, and decreases in liver weight, which are seen in chronic studies, alone, do not necessarily reflect an adverse effect. This is because liver weight changes have often been found to be reversible, in subchronic studies following the discontinuation of dosing, or through adaptation mechanisms, with the continued dietary intake of fenoxaprop-ethyl, in chronic studies.

LIQUID HYDROCARBONS

For olefins:

Studies have shown that normal alpha olefins have little or no toxic effect on animals except in very severe inhalation conditions and that they may produce minimal skin and eye irritation, but are not skin sensitizers. Laboratory exposures to very high airborne concentrations of C6-C16 normal alpha olefin vapors or mists produced central nervous system effects including anesthesia. If C20+ products are heated, fumes may produce nausea and irritation of the upper respiratory tract. Although not all products have been tested in genetic toxicity assays, the available data indicate normal alpha olefins are not mutagenic.

Acute toxicity: The weight of evidence indicates alpha and internal olefins with carbon numbers between C6 and C54 have a similar and low level of mammalian toxicity, and the toxicity profile is not affected by changes in the location of the double bond or the addition of branching to the structure. These materials are not eye irritants or skin sensitizers. Prolonged exposure of the skin for many hours may cause skin irritation.

Olefins (alkenes) ranging in carbon number from C6 to C24 alpha (linear) and internal (linear and branched), and C24-54 alpha (linear and branched) demonstrate low acute toxicity by the oral, inhalation and dermal routes of exposure: Rat oral LD50 >5 g/kg; rat 4-hr inhalation LC50 range = 110 mg/L (32,000 ppm) to 6.4 mg/L (693 ppm) for C6 to C16; and rat/rabbit dermal LD50 > highest doses tested (1.43-10 g/kg).

Repeated dose toxicity: Studies, using the inhalation (C6 alpha), dermal (C12-16 alpha), or oral (C6 alpha and internal linear/branched; C8 and C14 alpha; and C16/18, C18 and C20-24 internal linear/branched) routes of exposure, have shown comparable levels of low toxicity in rats. In females, alterations in body and organ weights, changes in certain clinical chemistry/haematology values, and liver effects were noted (NOELs of ≥ 100 mg/kg oral or ≥ 3.44 mg/kg [1000 ppm] inhalation). In males, alterations in organ weights, changes in certain clinical chemistry/hematology values, liver effects, and kidney damage were noted (LOELs ≥ 100 mg/kg oral only). The male rat kidney damage suggests alpha2u₁-globulin nephropathy, a male rat specific effect that is not considered relevant to human health. The noted liver effects were seen in oral studies with C14 alpha olefins (minimal-to-mild hepatocyte cytoplasmic vacuolation with increased liver weight in males and females) and with C20-24 internal olefins (minimal centrilobular hepatocyte hypertrophy with increased liver weight in females only). No effects were present in the study with C20-24 internal olefins following a 4-week recovery period, indicating reversibility of the observed effects. These liver effects seen only with the larger molecules may be indirect effects of an intensified liver

**N-METHYL-
2-PYRROLIDONE**

burden, rather than a direct toxic effect of the olefin. Based on evidence from neurotoxicity screens included in repeated dose studies with C6 and C14 alpha olefins and with C6, C16/18 and C20-24 internal linear/branched olefins, the category members are not neurotoxic.

Reproductive/ developmental toxicity: Based on evidence from reproductive/developmental toxicity screens in rats with C6 and C14 alpha olefins and C6 and C18 linear/branched internal olefins, along with the findings of no biologically significant effects on male or female reproductive organs in repeated dose toxicity studies, olefins are not expected to cause reproductive or developmental toxicity.

Genotoxicity: Based on the weight of evidence from studies with alpha and internal olefins, category members are not genotoxic.

Carcinogenicity: No carcinogenicity tests have been conducted on C6-54 alpha or internal olefins; however, there are no structural alerts indicating a potential for carcinogenicity in humans.

No significant acute toxicological data identified in literature search.

Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.

for N-methyl-2-pyrrolidone (NMP):

Acute toxicity: In rats, NMP is absorbed rapidly after inhalation, oral, and dermal administration, distributed throughout the organism, and eliminated mainly by hydroxylation to polar compounds, which are excreted via urine. About 80% of the administered dose is excreted as NMP and NMP metabolites within 24 h. A probably dose-dependent yellow coloration of the urine in rodents is observed. The major metabolite is 5-hydroxy-N-methyl-2-pyrrolidone.

Studies in humans show comparable results. Dermal penetration through human skin has been shown to be very rapid. NMP is rapidly biotransformed by hydroxylation to 5-hydroxy-N-methyl-2-pyrrolidone, which is further oxidized to N-methylsuccinimide; this intermediate is further hydroxylated to 2-hydroxy-N-methylsuccinimide. These metabolites are all colourless. The excreted amounts of NMP metabolites in the urine after inhalation or oral intake represented about 100% and 65% of the administered doses, respectively.

NMP has a low potential for skin irritation and a moderate potential for eye irritation in rabbits. Repeated daily doses of 450 mg/kg body weight administered to the skin caused painful and severe haemorrhage and eschar formation in rabbits. These adverse effects have not been seen in workers occupationally exposed to pure NMP, but they have been observed after dermal exposure to NMP used in cleaning processes. No sensitisation potential has been observed.

In acute toxicity studies in rodents, NMP showed low toxicity. Uptake of oral, dermal, or inhaled acutely toxic doses causes functional disturbances and depressions in the central nervous system. Local irritation effects were observed in the respiratory tract when NMP was inhaled and in the pyloric and gastrointestinal tracts after oral administration. In humans, there was no irritative effect in the respiratory system after an 8-h exposure to 50 mg/m³.

Repeat dose toxicity: There is no clear toxicity profile of NMP after multiple administration. In a 28-day dietary study in rats, a compound-related decrease in body weight gain was observed in males at 1234 mg/kg body weight and in females at 2268 mg/kg body weight. Testicular degeneration and atrophy in males and thymic atrophy in females were observed at these dose levels. The no-observed-adverse-effect level (NOAEL) was 429 mg/kg body weight in males and 1548 mg/kg body weight in females. In a 28-day intubation study in rats, a dose-dependent increase in relative liver and kidney weights and a decrease in lymphocyte count in both sexes were observed at 1028 mg/kg body weight. The NOAEL in this study was 514 mg/kg body weight. In another rat study, daily dietary intake for 90 days caused decreased body weights at doses of 433 and 565 mg/kg body weight in males and females, respectively. There were also neurobehavioural effects at these dose levels. The NOAELs in males and females were 169 and 217 mg/kg body weight, respectively.

The toxicity profile after exposure to airborne NMP depends strongly on the ratio of vapour to aerosol and on the area of exposure (i.e., head-only or whole-body exposure). Because of higher skin absorption for the aerosol, uptake is higher in animals exposed to aerosol than in those exposed to vapour at similar concentrations. Studies in female rats exposed head only to 1000 mg/m³ showed only minor nasal irritation, but massive mortality and severe effects on major organs were observed when the females were whole-body exposed to the same concentration of coarse droplets at high relative humidity. Several studies in rats following repeated exposure to NMP at concentrations between 100 and 1000 mg/m³ have shown systemic toxicity effects at the lower dose levels. In most of the studies, the effects were not observed after a 4-week observation period.

In rats, exposure to 3000 mg NMP/m³ (head only) for 6 h/day, 5 days/week, for 13 weeks caused a decrease in body weight gain, an increase in erythrocytes, haemoglobin, haematocrit, and mean corpuscular volume, decreased absolute testis weight, and cell loss in the germinal epithelium of the testes. The NOAEL was 500 mg/m³.

There are no data in humans after repeated-dose exposure.

Carcinogenicity: NMP did not show any clear evidence for carcinogenicity in rats exposed to concentrations up to 400 mg/m³ in a long-term inhalation study.

Genotoxicity: The mutagenic potential of NMP is weak. Only a slight increase in the number of revertants was observed when tested in a *Salmonella* assay with base-pair substitution strains. NMP has been shown to induce aneuploidy in yeast *Saccharomyces cerevisiae* cells. No investigations regarding mutagenicity in humans were available.

Reproductive toxicity: In a two-generation reproduction study in rats, whole-body exposure of both males and females to 478 mg/m³ of NMP vapour for 6 h/day, 7 days/week, for a minimum of 100 days (pre-mating, mating, gestation, and lactation periods) resulted in a 7% decrease in fetal weight in the F1 offspring. A 4-11% transient, non-dose-dependent decrease was observed in the average pup weight at all exposure levels tested (41, 206, and 478 mg/m³).

Developmental toxicity: When NMP was administered dermally, developmental toxicity was registered in rats at 750 mg/kg body weight. The observed effects were increased preimplantation losses, decreased fetal weights, and delayed ossification. The NOAEL for both developmental effects and maternal toxicity (decreased body weight gain) was 237 mg/kg body weight.

Inhalation studies in rats (whole-body exposure) demonstrated developmental toxicity as increased preimplantation loss without significant effect on implantation rate or number of live fetuses at 680 mg/m³ and behavioural developmental toxicity at 622 mg/m³. In an inhalation study (whole-body exposure), the NOAEL for maternal effects was 100 mg/m³, and the NOAEL for developmental effects was 360 mg/m³.

A tolerable inhalation concentration, 0.3 mg/m³, based on mortality and organ damage, is expected to be protective against any possible reproductive toxicity. Similarly, an oral tolerable intake of 0.6 mg/kg body weight per day, based on a 90-day study, is expected to provide adequate protection against possible reproductive effects. Because of non-existent data on the exposure of the general population and very limited information on occupational exposure, no meaningful risk characterisation can be performed.

A substance (or part of a group of chemical substances) of very high concern (SVHC) - or product containing an SVHC:

It is proposed that use within the European Union be subject to authorisation under the REACH Regulation. Indeed, listing of a substance as an SVHC by the European Chemicals Agency (ECHA) is the first step in the procedure for authorisation or restriction of use of a chemical.

The criteria are given in article 57 of the REACH Regulation. A substance may be proposed as an SVHC if it meets one or more of the following criteria:

- it is carcinogenic *;
- it is mutagenic *;
- it is toxic for reproduction *;
- it is persistent, bioaccumulative and toxic (PBT substances);
- it is very persistent and very bioaccumulative (vPvB substances);
- there is "scientific evidence of probable serious effects to human health or the environment which give rise to an equivalent level of concern"; such substances are identified on a case-by-case basis.

* Collectively described as CMR substances

The "equivalent concern" criterion is significant because it is this classification which allows substances which are, for example, neurotoxic, endocrine-disrupting or otherwise present an unanticipated environmental health risk to be regulated under REACH. Simply because a substance meets one or more of the criteria does not necessarily mean that it will be proposed as an SVHC.

Many such substances are already subject to restrictions on their use within the European Union, such as those in Annex XVII of the REACH Regulation. SVHCs are substances for which the current restrictions on use (where these exist) might be insufficient.

There are three priority groups for assessment:

- PBT substances and vPvB substances;
- substances which are widely dispersed during use;
- substances which are used in large quantities.

Acute Toxicity	✓	Carcinogenicity	✗
Skin Irritation/Corrosion	✓	Reproductivity	✓
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✓
Respiratory or Skin sensitisation	✗	STOT - Repeated Exposure	✗
Mutagenicity	✗	Aspiration Hazard	✓

Legend: ✗ – Data either not available or does not fill the criteria for classification
 ✓ – Data available to make classification

SECTION 12 Ecological information

Toxicity

AC Quiza PE 200	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
quizalofop-P-ethyl	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	96h	Algae or other aquatic plants	0.47-1.91mg/l	4
	EC50	48h	Crustacea	0.405-0.54mg/L	4
	EC50	72h	Algae or other aquatic plants	37.8-82.35mg/L	4
	NOEC(ECx)	816h	Fish	0.066mg/L	4
	LC50	96h	Fish	0.216-0.378mg/L	4
liquid hydrocarbons	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
N-methyl-2-pyrrolidone	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	48h	Crustacea	ca.4897mg/l	1

Continued...

	EC50	72h	Algae or other aquatic plants	>500mg/l	1
	NOEC(ECx)	504h	Crustacea	12.5mg/l	2
	LC50	96h	Fish	464mg/l	1

Legend: Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
quizalofop-P-ethyl	HIGH	HIGH
N-methyl-2-pyrrolidone	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
quizalofop-P-ethyl	HIGH (LogKOW = 5.4699)
N-methyl-2-pyrrolidone	LOW (BCF = 0.16)

Mobility in soil

Ingredient	Mobility
quizalofop-P-ethyl	LOW (KOC = 50030)
N-methyl-2-pyrrolidone	LOW (KOC = 20.94)



SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal	<ul style="list-style-type: none">Containers may still present a chemical hazard/ danger when empty.Return to supplier for reuse/ recycling if possible. Otherwise: <ul style="list-style-type: none">If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.Where possible retain label warnings and SDS and observe all notices pertaining to the product.
------------------------------	--

SECTION 14 Transport information

Labels Required

	
Marine Pollutant	
HAZCHEM	•3Z

Land transport (ADG)

14.1. UN number or ID number	3082
14.2. UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains quizalofop-P-ethyl)

14.3. Transport hazard class(es)	Class	9
	Subsidiary Hazard	Not Applicable
14.4. Packing group	III	
14.5. Environmental hazard	Environmentally hazardous	
14.6. Special precautions for user	Special provisions	274 331 335 375 AU01
	Limited quantity	5 L

Environmentally Hazardous Substances meeting the descriptions of UN 3077 or UN 3082 are not subject to this Code when transported by road or rail in;

(a) packagings;

(b) IBCs; or

(c) any other receptacle not exceeding 500 kg(L).

- Australian Special Provisions (SP AU01) - ADG Code 7th Ed.

Air transport (ICAO-IATA / DGR)

14.1. UN number	3082	
14.2. UN proper shipping name	Environmentally hazardous substance, liquid, n.o.s. (contains quizalofop-P-ethyl)	
14.3. Transport hazard class(es)	ICAO/IATA Class	9
	ICAO / IATA Subsidiary Hazard	Not Applicable
	ERG Code	9L
14.4. Packing group	III	
14.5. Environmental hazard	Environmentally hazardous	
14.6. Special precautions for user	Special provisions	A97 A158 A197 A215
	Cargo Only Packing Instructions	964
	Cargo Only Maximum Qty / Pack	450 L
	Passenger and Cargo Packing Instructions	964
	Passenger and Cargo Maximum Qty / Pack	450 L
	Passenger and Cargo Limited Quantity Packing Instructions	Y964
	Passenger and Cargo Limited Maximum Qty / Pack	30 kg G

Sea transport (IMDG-Code / GGVSee)

14.1. UN number	3082	
14.2. UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains quizalofop-P-ethyl)	
14.3. Transport hazard class(es)	IMDG Class	9
	IMDG Subsidiary Hazard	Not Applicable
14.4. Packing group	III	
14.5. Environmental hazard	Marine Pollutant	
14.6. Special precautions for user	EMS Number	F-A , S-F
	Special provisions	274 335 969
	Limited Quantities	5 L

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
quizalofop-P-ethyl	Not Available

Product name	Group
liquid hydrocarbons	Not Available
N-methyl-2-pyrrolidone	Not Available

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
quizalofop-P-ethyl	Not Available
liquid hydrocarbons	Not Available
N-methyl-2-pyrrolidone	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

quizalofop-P-ethyl is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Chemical Footprint Project - Chemicals of High Concern List

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

liquid hydrocarbons is found on the following regulatory lists

Not Applicable

N-methyl-2-pyrrolidone is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

Additional Regulatory Information

Not Applicable

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	No (quizalofop-P-ethyl)
Canada - DSL	No (quizalofop-P-ethyl)
Canada - NDSL	No (quizalofop-P-ethyl; N-methyl-2-pyrrolidone)
China - IECSC	No (quizalofop-P-ethyl)
Europe - EINEC / ELINCS / NLP	No (quizalofop-P-ethyl)
Japan - ENCS	No (quizalofop-P-ethyl)
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	No (quizalofop-P-ethyl)
USA - TSCA	No (quizalofop-P-ethyl)
Taiwan - TCSI	Yes
Mexico - INSQ	Yes
Vietnam - NCI	Yes
Russia - FBEPH	Yes
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.

SECTION 16 Other information

Revision Date	27/10/2023
Initial Date	26/08/2015

SDS Version Summary

Version	Date of Update	Sections Updated
8.1	10/03/2023	Classification change due to full database hazard calculation/update.
9.1	27/10/2023	UN Number update

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

- PC - TWA: Permissible Concentration-Time Weighted Average
- PC - STEL: Permissible Concentration-Short Term Exposure Limit
- IARC: International Agency for Research on Cancer
- ACGIH: American Conference of Governmental Industrial Hygienists
- STEL: Short Term Exposure Limit
- TEEL: Temporary Emergency Exposure Limit,
- IDLH: Immediately Dangerous to Life or Health Concentrations
- ES: Exposure Standard
- OSF: Odour Safety Factor
- NOAEL: No Observed Adverse Effect Level
- LOAEL: Lowest Observed Adverse Effect Level
- TLV: Threshold Limit Value
- LOD: Limit Of Detection
- OTV: Odour Threshold Value
- BCF: BioConcentration Factors
- BEI: Biological Exposure Index
- DNEL: Derived No-Effect Level
- PNEC: Predicted no-effect concentration

- AIIC: Australian Inventory of Industrial Chemicals
- DSL: Domestic Substances List
- NDSL: Non-Domestic Substances List
- IECSC: Inventory of Existing Chemical Substance in China
- EINECS: European INventory of Existing Commercial chemical Substances
- ELINCS: European List of Notified Chemical Substances
- NLP: No-Longer Polymers
- ENCS: Existing and New Chemical Substances Inventory
- KECI: Korea Existing Chemicals Inventory
- NZIoC: New Zealand Inventory of Chemicals
- PICCS: Philippine Inventory of Chemicals and Chemical Substances
- TSCA: Toxic Substances Control Act
- TCSI: Taiwan Chemical Substance Inventory
- INSQ: Inventario Nacional de Sustancias Químicas
- NCI: National Chemical Inventory
- FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.